2022
Outcomes by BCL2 and MYC expression and rearrangements in untreated diffuse large B-cell lymphoma (DLBCL) from the POLARIX trial.
Morschhauser F, Jiang Y, Jardin F, Herrera A, Sehn L, Herbaux C, Flowers C, Phillips T, Guillermo A, Diefenbach C, Gregory G, Kim A, Barbui A, Balasubramanian S, Harris W, Hirata J, Paulson J, Lee C, Lenz G. Outcomes by BCL2 and MYC expression and rearrangements in untreated diffuse large B-cell lymphoma (DLBCL) from the POLARIX trial. Journal Of Clinical Oncology 2022, 40: 7517-7517. DOI: 10.1200/jco.2022.40.16_suppl.7517.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaPola-R-CHPProgression-free survivalR-CHOPPrognostic impactMultivariate analysisBCL6-RUntreated diffuse large B-cell lymphomaProgression-free survival eventsProgression-free survival estimatesLarge B-cell lymphomaMultivariate Cox regression modelDouble expressor lymphomaSubgroups of ptsTranslocation of MYCTriple-hit lymphomaAssociated with poor outcomesB-cell lymphomaMYC protein expressionResults of univariate analysisCox regression modelsBCL2+Cell of originOverexpression of BCL2Fluorescence in situ hybridization
2019
Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell-of-origin: data from the phase III GOYA study
Bolen C, Klanova M, Trneny M, Sehn L, He J, Tong J, Paulson J, Kim E, Vitolo U, Di Rocco A, Fingerle-Rowson G, Nielsen T, Lenz G, Oestergaard M. Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell-of-origin: data from the phase III GOYA study. Haematologica 2019, 105: 2298-2307. PMID: 33054054, PMCID: PMC7556630, DOI: 10.3324/haematol.2019.227892.Peer-Reviewed Original ResearchConceptsDiffuse large B-cell lymphomaLarge B-cell lymphomaB-cell lymphomaPrognostic impact of somatic mutationsCell-of-origin subtypesBCL2 alterationsCell of originPrognostic impactImpact of somatic mutationsMolecular heterogeneity of diffuse large B-cell lymphomaGerminal center B-cell-like diffuse large B-cell lymphomaHeterogeneity of diffuse large B-cell lymphomaTargeted DNA next-generation sequencingAssociated with shorter progression-free survivalShorter progression-free survivalSomatic mutationsDNA next-generation sequencingParaffin-embedded tissue biopsiesProgression-free survivalMultivariate Cox regressionBCL2 translocationsUntreated patientsPotential treatment targetPrognostic differencesPrognostic effectS845 PREDICTED NEOANTIGENS PROVIDE PROGNOSTIC INSIGHT IN DLBCL
Paulson J, Jin D, Sokol E, Nielsen T, Venstrom J, Trabucco S. S845 PREDICTED NEOANTIGENS PROVIDE PROGNOSTIC INSIGHT IN DLBCL. HemaSphere 2019, 3: 377. DOI: 10.1097/01.hs9.0000561660.80605.a5.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaTumor mutational burdenComprehensive genomic profilingNeoantigen burdenImmune surveillanceClinical outcomesPrognostic insightsPoor outcomeEstimate tumor mutation burdenMedian tumor mutation burdenPersonalized cancer vaccine strategiesHigh tumor mutational burdenLarge B-cell lymphomaEvasion of immune surveillanceVaccination strategiesCancer vaccine strategiesAssociated with worsened outcomesB-cell lymphomaMultivariate Cox regressionImpact clinical outcomesCell of originMHC-I presentationBCL2 alterationsDLBCL cohortPrognostic factors